Dr. Kevin Joseph on Retatrutide: Physician's Overview Fact-Checked

Physician Dr. Kevin Joseph, who says he lost over 140 pounds using GLP-1 medications, published a video titled "Everything you need to know about Retatrutide, the newest GLP1 agonist." He walks through the mechanism of action, Phase 2 clinical trial results, and gives his take on who retatrutide might benefit most.

This is one of the better physician-led overviews on YouTube — Joseph explains the triple agonist mechanism clearly and gives a balanced assessment of pros and cons. But he gets a few details wrong, and some claims made before Phase 3 data were available have since been contradicted. This page checks his claims against the published evidence.

The Triple Agonist Mechanism: A Solid Explanation

"GLP-1 and GIP receptors are located in the hypothalamus, the GI tract, and pancreatic beta cells"

1:05

Joseph explains that retatrutide is a triple agonist acting on GLP-1, GIP, and glucagon receptors. He groups GLP-1 and GIP together and correctly identifies their locations and functions:

"GLP-1 and GIP receptors are located in the hypothalamus of the brain, in the GI tract, as well as pancreatic beta cells. This allows for their mechanism that they're most popular for — weight loss as well as glycemic control."

Joseph correctly identifies the three main locations (brain, gut, pancreas) and their functions. His explanation of the incretin effect — that these drugs help the body "recognize that signal again" in type 2 diabetics — is a clear and accurate simplification.

For the detailed mechanism, see How Retatrutide Works.

The Glucagon Component: Mostly Right

"Glucagon receptors are located primarily on the liver and kidney"

3:01

Joseph explains what sets retatrutide apart from semaglutide and tirzepatide — the glucagon receptor. He describes its role in blood sugar regulation, lipolysis, and brown adipose tissue activation:

"Glucagon breaks down glucose storage in the liver to bring the blood sugar up... Glucagon also plays a role in lipolysis or fat breakdown... Glucagon receptors are also located on brown adipose tissue. By acting on this pathway it increases energy expenditure and increases metabolic activity."

This is a strong explanation of the glucagon component. Joseph correctly identifies brown adipose tissue activation as a key differentiator and explains the homeostatic balance between insulin and glucagon clearly. His note about physiological vs. pharmacological glucagon levels is a nuance many YouTube creators miss entirely.

Phase 2 Results: Right Ballpark, Wrong Details

"Participants losing almost 18% of their body weight in 24 weeks"

5:19

Joseph walks through the Phase 2 trial results but mixes up a key detail — he attributes the maximum 24-week weight loss to the wrong dose:

"The largest percentage of weight loss occurring on 8 milligrams with participants losing almost 18% of their body weight in 24 weeks."

Joseph gets the 48-week headline number right (-24.2% at 12 mg) but misattributes the 24-week maximum to 8 mg instead of 12 mg. The 8 mg groups did show strong results (-12.9% to -17.1% at 24 weeks depending on titration), but the maximum was in the 12 mg group. He also correctly notes the difference between primary (24-week) and secondary (48-week) endpoints.

For the full trial data, see Retatrutide Results. For dosing details, see Retatrutide Dosage.

Retatrutide vs Tirzepatide: A Valid Comparison

"Participants lost more weight in two-thirds of the time compared to tirzepatide"

6:33

Joseph compares the Phase 2 retatrutide data to the tirzepatide SURMOUNT-1 trial:

"At 48 weeks the largest percentage of weight loss was at 12 mg where individuals lost almost 24% of their starting body weight. The only other thing we can compare this to is the tirzepatide clinical trial on obesity where participants lost 21% of their starting weight but over 72 weeks."

His cross-trial comparison is approximately accurate — tirzepatide showed -20.9% at 72 weeks (he rounds to 21%), and retatrutide showed -24.2% at 48 weeks. His point that retatrutide achieved more weight loss in less time is valid for these cross-trial numbers.

However, cross-trial comparisons have limitations: different patient populations, enrollment criteria, and study designs. Since Joseph recorded this video, Phase 3 TRIUMPH-4 data has been published (December 2025), showing -28.7% weight loss at 12 mg over 68 weeks — even stronger than the Phase 2 data he cites. The ongoing TRIUMPH-5 head-to-head trial against tirzepatide will provide a definitive comparison.

For the full comparison, see Retatrutide vs Mounjaro.

The Hypoglycemia Argument: Plausible but Unproven

"Activating the glucagon receptor helps break down glycogen stores and release glucose"

7:58

Joseph argues that the glucagon component could reduce hypoglycemia risk compared to other GLP-1 medications:

"Glucagon acts in the opposite manner of insulin. Activating the glucagon receptor activates glycogen or glucose stores that are in the liver and helps break down those glycogen stores and releases that glucose into the bloodstream to help balance out your blood sugar."

The physiology is sound — glucagon does counteract insulin. But clinical trial data has not demonstrated that retatrutide causes meaningfully less hypoglycemia than other GLP-1 drugs. In Phase 2, hypoglycemia was rare across all groups (including placebo), making it hard to show a difference. This remains a theoretical benefit that may require specific study in diabetic populations where hypoglycemia risk is higher.

"Fewer Side Effects": Not What Phase 3 Shows

"Because it's a triple agonist, it does not bind as strongly to the GLP-1 receptor"

11:16

Joseph makes a pharmacological argument that retatrutide should have fewer GI side effects because it spreads its activity across three receptors instead of concentrating it on GLP-1:

"Semaglutide has a lot more side effects than tirzepatide... and I think that has a lot to do with how strong semaglutide binds to the GLP-1 receptor. Because retatrutide is a triple agonist, it does not bind as strongly to the GLP-1 or GIP receptor, which prevents side effects."

Joseph is right that semaglutide has higher GI side effect rates than tirzepatide — this is well-established. But his extrapolation that retatrutide would have even fewer side effects has been contradicted by Phase 3 data. TRIUMPH-4 showed nausea rates of 43.2% at 12 mg — comparable to semaglutide and significantly higher than tirzepatide.

Phase 3 also revealed a novel safety signal not seen in Phase 2: dysesthesia (abnormal skin sensations like tingling or burning) occurred in 20.9% of participants on 12 mg retatrutide vs. 0.7% on placebo. Joseph could not have known about this when he recorded the video, but it underscores why Phase 2 data alone is insufficient for assessing a drug's side effect profile.

For the full safety data, see Retatrutide Side Effects.

Non-Responders: Reasonable Speculation

"Because of this extra pathway, I'm hoping retatrutide may bring hope for non-responders"

9:50

Joseph identifies a patient population he thinks could benefit most from retatrutide — non-responders to semaglutide and tirzepatide:

"Non-responders to GLP-1s are patients who are at the maximum dose — either 15 mg for tirzepatide or 2.4 mg for semaglutide — and they're not having any sort of weight loss. Because of this extra pathway that retatrutide acts on, the glucagon pathway, it may bring hope for non-responders."

This is speculative but well-reasoned. There is no published clinical data on switching non-responders to retatrutide. However, the logic is sound: if a patient does not respond adequately to GLP-1 and GIP receptor activation alone, adding glucagon receptor activation — which drives fat oxidation and energy expenditure through a different mechanism — could provide additional benefit.

Joseph correctly notes the max doses (tirzepatide 15 mg for weight loss, semaglutide 2.4 mg for weight loss) and acknowledges this is a hypothesis rather than established fact. This is exactly the kind of nuanced clinical thinking that separates physician content from influencer content.

For switching guidance, see Switching to Retatrutide.

Frequently Asked Questions

Sources

• Joseph, K. (2024). "Everything you need to know about Retatrutide, the newest GLP1 agonist." YouTube. Watch on YouTube
• Jastreboff, A.M., et al. (2023). Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine. DOI: 10.1056/NEJMoa2301972
• Eli Lilly and Company. (2025). TRIUMPH-4 results press release. Press release
• Jastreboff, A.M., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine (SURMOUNT-1). DOI: 10.1056/NEJMoa2206038
• Wilding, J.P.H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine. DOI: 10.1056/NEJMoa2032183
• Li, W., et al. (2024). Structural insights into the triple agonism at GLP-1R, GIPR and GCGR manifested by retatrutide. Cell Discovery. DOI: 10.1038/s41421-024-00700-0

Medical Disclaimer

The content on glp3.wiki is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Retatrutide is an investigational drug that has not been approved by the U.S. Food and Drug Administration (FDA) or any other regulatory agency.

Dr. Kevin Joseph's video is not a substitute for professional medical advice. While he provides a generally accurate overview based on Phase 2 data available at the time, some of his predictions about side effects have since been contradicted by Phase 3 results.

Do not use this information to make decisions about your health without consulting a qualified healthcare provider. Always discuss treatment options with your doctor.

This site is not affiliated with Dr. Kevin Joseph, Eli Lilly and Company, or any pharmaceutical manufacturer.